Kymera Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kymera Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 4 currently recruiting 6 completed early-phase tilt top decile by trial count

Kymera Therapeutics: 10 sponsored US clinical trials, 4 recruiting.

Kymera Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 2 trials.

Top-decile sponsor footprint

Kymera Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

NCT07677059
RECRUITING Phase 1

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

NCT07412288
RECRUITING Phase 2

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
RECRUITING Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT07217015
COMPLETED Phase 1

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458
COMPLETED Phase 1

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

NCT06673667
COMPLETED Phase 1

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

NCT05775406
COMPLETED Phase 1

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

NCT05233033
COMPLETED Phase 1

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584
COMPLETED Phase 1

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 3

Therapeutic Areas

Atopic Dermatitis 2
MYD88 Gene Mutation 1
Eosinophilic Asthma 1
DLBCL 1
Non-Hodgkin Lymphoma 1
Diffuse Large B Cell Lymphoma 1
Healthy Participants 1

What is open in the Kymera Therapeutics pipeline

4 recruiting of 10 indexed (40% open); 6 completed (60%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Atopic Dermatitis (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kymera Therapeutics: open-pipeline peers nationwide

Peers matched on 10 registered trials and 40% open enrollment, not the therapeutic-area sidebar.

Kymera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40%50% Total trials Recruiting share Kymera TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAd scientiamAlto NeuroscienceBonafide HealthBrooks Rehabilitation
Kymera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kymera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 40% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kymera Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Kymera Therapeutics or any single study.

  • 4 of Kymera Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Atopic Dermatitis is the condition Kymera Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kymera Therapeutics pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.